Koning Jerry Pharmaceuticals - B (09966.HK) announced that the latest research results of the Phase I/II clinical trial of JSKN033, a drug developed independently by the group for treating HER2-expressing advanced or metastatic solid tumors, have been selected for the 2024 SITC Annual Meeting latest breakthrough abstract, and will be first publicly disclosed in poster form during the conference. The conclusion is that JSKN033 has good safety and shows promising anti-tumor activity in preliminary patients with solid tumors experiencing disease progression after multiple lines of treatment.
康寧傑瑞製藥(09966.HK)JSKN033研究成果入選SITC年會最新突破性摘要
Kangning Jerry Pharmaceuticals (09966.HK) JSKN033 research results selected for the latest breakthrough abstract at the SITC Annual Meeting.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated